Einloggen
E-Mail
Passwort
Passwort anzeigen
Merken
Passwort vergessen?
Werden Sie kostenlos Mitglied
Registrieren
Registrieren
Mitglied werden
Kostenlos registrieren
Abonnent werden
Unser Angebot
Einstellungen
Einstellungen
Dynamische Kurse 
OFFON
  1. Startseite
  2. Aktien
  3. Schweiz
  4. Swiss Exchange
  5. BB Biotech AG
  6. News
  7. Übersicht
    BION   CH0038389992

BB BIOTECH AG

(A0NFN3)
  Bericht
Realtime Estimate-Kurse. Realtime-Estimate  - 26.11. 17:20:00
77.8500 CHF   +0.71%
22.10.Aktien Schweiz gut behauptet - Überzeugende Bilanzsaison stützt
DJ
22.10.Morning Briefing - Markt Schweiz
AW
22.10.BB Biotech steigert trotz Verlust im Q3 Gewinn für erste 9 Monate
AW
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivate 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-NewsMarketScreener Analysen

Shareholders at BB Biotech AG's AGM vote in favor of all proposals and approve the dividend of CHF 3.60 per share (english)

18.03.2021 | 17:45

    Shareholders at BB Biotech AG's AGM vote in favor of all proposals and approve the dividend of
CHF 3.60 per share

^
DGAP-News: BB BIOTECH AG / Key word(s): AGM/EGM/Dividend
Shareholders at BB Biotech AG's AGM vote in favor of all proposals and
approve the dividend of CHF 3.60 per share

18.03.2021 / 17:45
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Media Release as of March 18, 2021

Shareholders at BB Biotech AG's AGM vote in favor of all proposals and
approve the dividend of CHF 3.60 per share

All proposals of BB Biotech AG's Board of Directors were approved by
shareholders at its Annual General Meeting held today. In accordance with
the COVID-19 Ordinance 2, the voting rights of shareholders were exclusively
exercised through the independent proxy as per their instructions, since
shareholders were not allowed to attend the meeting in person.

Shareholders voted in favor of the proposal to pay out a dividend of CHF
3.60 per share. Payment will be made on March 24, 2021, the record date is
March 23, 2021 and the ex-dividend date is March 22, 2021.

Shareholders elected the previous board members Dr. Erich Hunziker,
Chairman, Dr. Clive Meanwell, Dr. Susan Galbraith, Prof. Dr. Mads Krogsgaard
Thomsen and Dr. Thomas von Planta to another one-year term of office.

Investor Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland,
Tel. +41 44 267 67 00
Dr. Silvia Schanz, ssc@bellevue.ch
Maria-Grazia Iten-Alderuccio, mga@bellevue.ch
Claude Mikkelsen, cmi@bellevue.ch

Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland,
Tel. +41 44 267 67 00
Tanja Chicherio, tch@bellevue.ch

TE Communications AG, St. Leonhard-Strasse 45, 9001 St. Gallen, Switzerland,
Tel. +41 79 423 22 28
Thomas Egger, teg@te-communications.ch

www.bbbiotech.com

Company profile
BB Biotech AG is an investment company domiciled in Schaffhausen/Switzerland
and listed on the stock exchanges in Switzerland, Germany and Italy. Since
1993, the company has invested in innovative drug development companies that
are mainly located in the US and Western Europe. BB Biotech is one of the
leading investors in this sector. BB Biotech builds on the long-standing
experience of its distinguished Board of Directors and on the fundamental
analysis of the experienced Investment Management Team of Bellevue Asset
Management AG when making its investment decisions.

Disclaimer
This release contains forward-looking statements and expectations as well as
assessments, beliefs and assumptions. Such statements are based on the
current expectations of BB Biotech, its directors and officers, and are,
therefore, subject to risks and uncertainties that may change over time. As
actual developments may significantly differ, BB Biotech and its directors
and officers accept no responsibility in that regard. All forward-looking
statements included in this release are made only as of the date of this
release and BB Biotech and its directors and officers undertake no
obligation to update any forward-looking statements as a result of new
information, future events or other factors.


---------------------------------------------------------------------------

18.03.2021 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------

   Language:       English
   Company:        BB BIOTECH AG
                   Schwertstrasse 6
                   8200 Schaffhausen
                   Switzerland
   Phone:          +41 52 624 08 45
   E-mail:         info@bbbiotech.com
   Internet:       www.bbbiotech.ch
   ISIN:           CH0038389992
   WKN:            A0NFN3
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Mailand, SIX
   EQS News ID:    1176751



   End of News    DGAP News Service
---------------------------------------------------------------------------

1176751 18.03.2021

°






© dpa-AFX 2021
Alle Nachrichten zu BB BIOTECH AG
22.10.Aktien Schweiz gut behauptet - Überzeugende Bilanzsaison stützt
DJ
22.10.Morning Briefing - Markt Schweiz
AW
22.10.BB Biotech steigert trotz Verlust im Q3 Gewinn für erste 9 Monate
AW
22.10.BB Biotech schrumpft Nettoverlust in Q3
MT
22.10.BB BIOTECH : Zwischenbericht per 30. September 2021
PU
22.10.BB BIOTECH : baut Positionen im Bereich Onkologie und ZNS aus
PU
22.10.BB BIOTECH : veröffentlicht Zwischenbericht
EQ
22.10.BB BIOTECH : Gewinnrealisierungen infolge der COVID-19-Impfauffrischungs-Neuigkeiten ermög..
EQ
22.10.BB Biotech AG veröffentlicht Zwischenbericht
DP
22.10.BB BIOTECH : Gewinnrealisierungen infolge der COVID-19-Impfauffrischungs-Neuigkeiten ermög..
DP
Weitere Nachrichten
News auf Englisch zu BB BIOTECH AG
23.10.BB Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
22.10.BB BIOTECH : Q3 Net Loss Shrinks
MT
22.10.BB BIOTECH : increases positions in oncology and CNS
PU
22.10.BB BIOTECH : publishes its interim report
EQ
22.10.BB BIOTECH : Gains realized following COVID-19 vaccine booster update enable increases in ..
EQ
23.07.Bb Biotech Ag Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
23.07.BB BIOTECH : Posts Lower H1 Profit, Operating Income
MT
23.07.BB BIOTECH : Interim report as at June 30, 2021
PU
23.07.BB BIOTECH : publishes its interim report
EQ
23.07.BB BIOTECH : Solid second quarter for the biotech industry - BB Biotech raised its allocat..
EQ
Weitere Nachrichten auf Englisch
Analystenempfehlungen zu BB BIOTECH AG
Mehr Empfehlungen
Finanzkennziffern
Umsatz 2021 -175 Mio -189 Mio -167 Mio
Nettoergebnis 2021 439 Mio 474 Mio 421 Mio
Nettoverschuldung 2021 23,5 Mio 25,3 Mio 22,4 Mio
KGV 2021 7,67x
Dividendenrendite 2021 5,15%
Marktkapitalisierung 4 321 Mio 4 682 Mio 4 135 Mio
Marktkap. / Umsatz 2021 -24,8x
Marktkap. / Umsatz 2022 -
Mitarbeiterzahl 10
Streubesitz 98,1%
Chart BB BIOTECH AG
Dauer : Zeitraum :
BB Biotech AG : Chartanalyse BB Biotech AG | MarketScreener
Vollbild-Chart
Chartanalyse-Trends BB BIOTECH AG
KurzfristigMittelfristigLangfristig
TrendsFallendFallendFallend
Ergebnisentwicklung
Analystenschätzung
Verkaufen
Kaufen
Durchschnittl. Empfehlung AUFSTOCKEN
Anzahl Analysten 4
Letzter Schlusskurs 78,00 CHF
Mittleres Kursziel 97,00 CHF
Abstand / Durchschnittliches Kursziel 24,4%
Verlauf des Gewinns je Aktie
Vorstände und Aufsichtsräte
Michael Hutter Head-Finance & Compliance
Erich Hunziker Chairman-Supervisory Board
Daniel Koller Head-Investment Management
Clive A. Meanwell Vice Chairman-Supervisory Board
Thomas von Planta Member-Supervisory Board
Branche und Wettbewerber
01.01.Wert (M$)
BB BIOTECH AG4.25%4 578
MODERNA, INC.161.69%110 846
LONZA GROUP AG25.95%56 890
IQVIA HOLDINGS INC.48.11%50 694
SEAGEN INC.-1.11%31 671
CELLTRION, INC.-40.39%23 975